Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Start Midwest

Neither a doctor nor a teaching hospital

Research payments

$10,008,594

1,748 payments

Through program year 2025, Start Midwest is reported as receiving $10,008,594 in research payments, across 1,748 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,270,522 458
2024 Research $830,705 188
2023 Research $1,414,226 354
2022 Research $1,073,401 70
2021 Research $1,134,416 92
2020 Research $1,180,802 198
2019 Research $2,104,524 388

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $3,542,009 582 payments
  2. Incyte Corporation $1,385,739 418 payments
  3. E.R. Squibb & Sons, L.L.C. $1,372,070 18 payments
  4. Pfizer Inc. $1,315,084 169 payments
  5. TESARO, Inc. $760,498 8 payments
  6. AbbVie, Inc. $620,473 321 payments
  7. GlaxoSmithKline, LLC. $348,093 28 payments
  8. Regeneron Pharmaceuticals, Inc. $277,358 83 payments
  9. Deciphera Pharmaceuticals Inc. $207,654 70 payments
  10. Helsinn Healthcare SA $140,439 43 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors $1,171,843 312 payments
  2. Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Compared to Niraparib Capsule $760,498 8 payments
  3. A Phase 1 Openlabel Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of Pf07284892 Arry558 As A Single Agent and in Combination Therapy in Participants With Advanced Solid Tumors $716,571 38 payments
  4. A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 with or without Bevacizumab in Advanced Solid Tumors $445,431 2 payments
  5. A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in combination with Pembrolizumab in Patients with Advanced Malignancies $424,378 51 payments
  6. An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors $422,300 3 payments
  7. A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects with Advanced Solid Tumors $369,832 53 payments
  8. A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors $361,841 15 payments
  9. Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors $353,375 211 payments
  10. A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in combination with Pembrolizumab in Patients with Advanced Malignancies $340,742 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record